HWPC(688799) 证券时报网·2024-12-25 04:53Core Viewpoint - Warner Pharmaceuticals' subsidiary has received approval for two active pharmaceutical ingredients, enhancing its product line and competitive edge in the market [1][6]. Group 1: Regulatory Approvals - Warner Pharmaceuticals' subsidiary, Hunan Warner Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the active pharmaceutical ingredients, Ropivacaine and Diquafosol Sodium, with a joint review result of "A" [1][4]. - The approval of these two active pharmaceutical ingredients will further enrich the company's product line and strengthen its "integrated raw material and formulation" advantage [6]. Group 2: Market Performance - Ropivacaine injection has been included multiple times in the shortage drug list, with sales exceeding 1.5 billion yuan in public medical institutions in China in 2023 [2]. - Diquafosol Sodium eye drops generated total sales of $18.9 million in 2023 across 71 countries, indicating a significant market presence [3]. Group 3: Product Applications - Ropivacaine is an alpha-adrenergic receptor agonist used for treating acute hypotension during epidural anesthesia and for symptomatic treatment of hypotension due to various medical conditions [6]. - Diquafosol Sodium is a P2Y2 receptor agonist indicated for patients with dry eye associated with tear film abnormalities [5].